← Back to patent-cliff list
美阿沙坦钾
Tier C — Watch / tradeAzilsartan Medoxomil Potassium
武田药品工业株式会社
Originator
2011
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：AT1
Brand：Ipreziv、易达比、Edarbi
Indications (approved)：原发性高血压、高血压
Regional status
US
批准上市
2011-02-25
EU
批准上市
2011-12-07
China
批准上市
2021-01-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Azilsartan Medoxomil Potassium?
Approved indications include: 原发性高血压, 高血压.
When does the Azilsartan Medoxomil Potassium patent expire?
No public expiry year is available for Azilsartan Medoxomil Potassium yet; this page updates once verified.
How do I get a quote for Azilsartan Medoxomil Potassium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25